<DOC>
	<DOCNO>NCT02443064</DOCNO>
	<brief_summary>1 . Drug resistance G+ cocci severe healthcare problem . According Ministry Health National Antimicrobial Resistant Investigation Net ( mohnarin ) surveillance report , isolation rate MRSA 60 % China . MRSA infection become serious clinical problem ; 2 . Vancomycin bactericidal glycopeptide antibiotic inhibits bacterial growth hinder synthesis cell wall bacteria . It exert strong antibiotic effect Gram+ bacteria . It indicate serious staphylococcus infection especially MRSA infection become gold standard agent MRSA treatment ; 3 . Vancomycin time-dependent antibiotic , clinical microbiological efficacy related area curve（ AUC）/minimum inhibitory concentration （MIC ） ( AUIC ) . Cmin steady state surrogate parameter AUIC , closely associated efficacy ; 4 . AUIC &gt; 400 Cmin 15~20 mg/L recommend effective vancomycin treatment Infectious Diseases Society America （IDSA） although still disputable ; 5 . Due absence PK/PD study vancomycin China , administration vancomycin perform reference recommendation IDSA . Its suitability Chinese patient still clarify ; 6 . Plasma concentration vancomycin vary significantly population individual . Factors large-volume fluid infusion , hypoproteinemia renal clearance , etc . influence distribution excretion vancomycin , result different plasma concentration individual . Results PK study differ greatly China abroad . Administration base AUIC Cmin recommend IDSA would suitable Chinese patient . Given definite long-term benefit vancomycin treatment , AUIC Cmin suitable Chinese patient must identify clinical study . 7 . The PK/PD study vancomycin treatment MRSA septicemia endocarditis great significance reasonable use improve therapeutic efficacy MRSA infection .</brief_summary>
	<brief_title>Pharmacokinetics/ Pharmacodynamics ( PK/PD ) Study Vancomycin</brief_title>
	<detailed_description>Study design : A multi-center , non-controlled , open-labeled observational study Research objectives Primary objective : To explore PK/PD target value ( AUIC ) vancomycin treatment MRSA septicemia endocarditis Chinese patient . Secondary objective : To detect therapeutic efficacy safety vancomycin treatment MRSA septicemia endocarditis Chinese patient . To exam relationship Cmin vancomycin efficacy treatment MRSA septicemia endocarditis . To explore relationship MRSA molecular type vancomycin therapeutic efficacy Medicine administration Drug : Vancomycin Dosing : 15~20 mg/kg , IV , q 12~8h ( 1 g , IV , q12~8h ) adult patient normal renal function ; Dosage adjust blood creatinine clearance patient impaired renal function ; Administration route： 1~2 h/ dosing , IV Drug combination : Drug combination recommend patient simple MRSA infection ; Rifampicin combine case MRSA artificial valve endocarditis ; Anti-G- antibacterial agent combine case concurrent G- bacterial infection . Duration : Septicemia : 2~4 week Endocarditis : 6~8 week</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>1 . Age ≥18 year , male female ; 2. diagnose MRSA septicemia endocarditis ; Septicemia clinical manifestation infection ; MRSA infection confirm blood culture ; Endocarditis : diagnose accord modify Duke Criteria 3. therapy effective antiMRSA drug 72 hour prior study ; Effective antiMRSA drug use China include : vancomycin , norvancomycin , teicoplanin , linezolid , daptomycin , tigecycline , fusidic acid . 1. allergic glycopeptides antibiotic ; 2. osteomyelitis , central nervous system infection septic migration ( except endocarditis ) ; 3. patient catheterrelated bloodstream infection withdraw catheter ; 4. chemotherapy cancer leukemia ; 5. agranulocytosis ; 6. HIV infection ; 7. woman pregnancy lactation ; 8. patient receive vancomycin le 72 hour ; 9. patient participate clinical trial 3 month prior study ( limited trial antibiotic )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Pharmacokinetics/pharmacodynamics</keyword>
	<keyword>vancomycin</keyword>
	<keyword>blood stream infection</keyword>
	<keyword>Chinese patient</keyword>
	<keyword>MRSA</keyword>
</DOC>